Literature DB >> 19859996

Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116.

Qing Ye1, Bo Feng, Yuan-Fei Peng, Xue-Hua Chen, Qu Cai, Bei-Qin Yu, Liang-Hui Li, Ming-Yuan Qiu, Bing-Ya Liu, Min-Hua Zheng.   

Abstract

AIM: To investigate the expression pattern of gamma-synuclein in colorectal cancer (CRC) tissues, and to study the effects of gamma-synuclein on CRC cell line HCT116 biological features in vitro.
METHODS: The expression pattern of gamma-synuclein was determined in 54 CRC tissues and 30 tumor-matched nonneoplastic adjacent tissues (NNAT) 5 cm away from the tumor via real-time quantitative reverse transcription PCR (RT-PCR) and immunohistochemistry. The relationship between gamma-synuclein protein expression and clinicopathological factors of CRC tissues was analyzed. Three small interfering RNA (siRNA) targeting gamma-synuclein mRNA plasmids were constructed and transfected into the CRC cell line HCT116. The stable cell lines were selected with G-418 for 28 d, and the biological features of these cells were examined by cell growth curve, soft agar assay, and cell migration and invasion assays in vitro.
RESULTS: The expression of gamma-synuclein mRNA and protein was much higher in CRC tissue samples than in NNAT samples (P = 0.02, P = 0.036). There was a significant correlation between the gamma-synuclein protein expression and clinical stage and lymph node involvement of CRC (P = 0.02, P = 0.033). In functional analysis we found that down-regulation of gamma-synuclein expression in HCT116 cells could inhibit the growth, colony formation rate, and migration and invasion ability of HCT116 cells.
CONCLUSION: Increased expression of gamma-synuclein in CRC tissues and the biological effects of reduced gamma-synuclein expression on HCT116 cells suggest that gamma-synuclein may play a positive role in the progression of CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19859996      PMCID: PMC2768882          DOI: 10.3748/wjg.15.5035

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1.

Authors:  Yinghui Mao; Ariane Abrieu; Don W Cleveland
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

2.  Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma.

Authors:  Y E Liu; W Pu; Y Jiang; D Shi; R Dackour; Y E Shi
Journal:  Oncogene       Date:  2006-10-02       Impact factor: 9.867

3.  Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.

Authors:  Satoru Inaba; Cong Li; Y Eric Shi; Dan-Qing Song; Jian-Dong Jiang; Jingwen Liu
Journal:  Breast Cancer Res Treat       Date:  2005-11       Impact factor: 4.872

4.  Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.

Authors:  Vladimir N Uversky; Jie Li; Pierre Souillac; Ian S Millett; Sebastian Doniach; Ross Jakes; Michel Goedert; Anthony L Fink
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

5.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.

Authors:  June-Young Park; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-04-08       Impact factor: 3.162

6.  Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.

Authors:  Vinay K Singh; Yue Zhou; Joseph A Marsh; Vladimir N Uversky; Julie D Forman-Kay; Jingwen Liu; Zongchao Jia
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

7.  Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways.

Authors:  Zhong-Zong Pan; Wendy Bruening; Benoit I Giasson; Virginia M-Y Lee; Andrew K Godwin
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

8.  Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas.

Authors:  Kar-Ming Fung; Lucy B Rorke; Benoit Giasson; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2003-05-28       Impact factor: 17.088

9.  Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.

Authors:  Irina G Surgucheva; Jeremy M Sivak; M Elizabeth Fini; Robert E Palazzo; Andrei P Surguchov
Journal:  Arch Biochem Biophys       Date:  2003-02-01       Impact factor: 4.013

Review 10.  Colorectal cancer: what has changed in diagnosis and treatment over the last 50 years?

Authors:  Leandro Gennari; Antonio Russo; Carlo Rossetti
Journal:  Tumori       Date:  2007 May-Jun
View more
  12 in total

1.  Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Susanna Syriac; Heidi Godoy; Nefertiti Dupont; Song Liu; Kunle Odunsi
Journal:  Gynecol Oncol       Date:  2011-10-19       Impact factor: 5.482

2.  Expression of SNCG, MAP2, SDF-1 and CXCR4 in gastric adenocarcinoma and their clinical significance.

Authors:  Shufang Zheng; Lifang Shi; Yi Zhang; Tao He
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  [Culture and identification of tumor stem cells from surgically resected colorectal cancer tissues].

Authors:  Na Tang; Lue Zhou; Zhiqiang Cheng; Yongjian Deng; Yanqing Ding
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-04-30

4.  γ-Synuclein confers both pro-invasive and doxorubicin-mediated pro-apoptotic properties to the colon adenocarcinoma LS 174T cell line.

Authors:  Kai-Wey Goh; Yee-How Say
Journal:  Tumour Biol       Date:  2015-05-09

5.  Expression of ERα, its ERαΔ3 Splice Variant and γ-SYNUCLEIN in Ovarian Cancer: A Pilot Study.

Authors:  Karen T Cheung; Siân E Taylor; Imran I Patel; Adam J Bentley; Helen F Stringfellow; Nigel J Fullwood; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Br J Med Med Res       Date:  2011-10

6.  Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma.

Authors:  Shaiju K Vareed; Vadiraja B Bhat; Christopher Thompson; Vihas T Vasu; Damian Fermin; Hyungwon Choi; Chad J Creighton; Sitaram Gayatri; Ling Lan; Nagireddy Putluri; Gagan Singh Thangjam; Punit Kaur; Mohsen Shabahang; Judith G Giri; Alexey I Nesvizhskii; Alexander A A Asea; Anil G Cashikar; Arundhati Rao; James McLoughlin; Arun Sreekumar
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

7.  Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Joshua Kesterson; Susanna Syriac; Kimberly Clark; Peter J Frederick; Shashikant Lele; Song Liu
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

8.  MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer.

Authors:  Wenpeng Zhang; Tao Zhang; Runsen Jin; Hongchao Zhao; Jin Hu; Bo Feng; Lu Zang; Minhua Zheng; Mingliang Wang
Journal:  J Exp Clin Cancer Res       Date:  2014-12-31

9.  Modulation of dendritic cell function by the radiation-mediated secretory protein γ-synuclein.

Authors:  S-M Kang; M-H Kim; K-H Song; S-Y Jung; J Ahn; S-G Hwang; J-H Lee; D-S Lim; J-Y Song
Journal:  Cell Death Discov       Date:  2015-07-27

10.  Cellular prion protein and γ-synuclein overexpression in LS 174T colorectal cancer cell drives endothelial proliferation-to-differentiation switch.

Authors:  Sing-Hui Ong; Kai-Wey Goh; Cornelius Kwang-Lee Chieng; Yee-How Say
Journal:  PeerJ       Date:  2018-03-06       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.